

INFORMATION DISCLOSURE
STATEMENT
Patent Application
Docket No. GJE-207CD1

December 15, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : John Gary Montana, Andrew Douglas Baxter, David Alan Owen, Robert John Watson
Docket No. : GJE-207CD1
For : Hydroxamic and Carboxylic Acid Derivatives

Mail Stop PATENT APPLICATION
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.97 and §1.98, Applicants would like to bring to the attention of the Examiner, the references cited in the following patent applications:

U.S. Serial No. 09/777,522, filed February 6, 2001; and

U.S. Serial No. 09/244,739, filed February 5, 1999, now abandoned.

The subject application claims the benefit under 35 USC §120 of the filing date of patent applications 09/777,522 and 09/244,739. Applicants respectfully request that the copies of references supplied in the Information Disclosure Statements of the 09/777,522 and 09/244,739 applications, as well as any references cited during the prosecution thereof, be made of record in the subject application. As copies of the references made of record in the 09/777,522 and 09/244,739 applications, and cited on the attached form PTO/SB/08, can be found in the 09/777,522 and 09/244,739 casefiles, copies of those references are not provided herewith.

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statements.

Respectfully submitted,



Doran R. Pace
Patent Attorney
Registration No. 38,261
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: 2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669

DRP/sl

Attachment: Form PTO/SB/08



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet				Application Number	
				Filing Date	December 15, 2003
				First Named Inventor	John Gary Montana
				Art Unit	
				Examiner Name	
1	of	2	Attorney Docket Number	GJE-207CD1	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
U1	US-5,932,595		08-03-1999	Bender et al.	All
U2	US-6,187,924 B1		02-13-2001	Baxter et al.	All
U3	US-				
U4	US-				
U5	US-				
U6	US-				
U7	US-				
U8	US-				
U9	US-				

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)			
F1	EP 0780386		06-25-1997		All
F2	WO 96/35714		11-14-1996		All
F3					
F4					
F5					
F6					
F7					

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet	2	of	2	Application Number	
				Filing Date	December 15, 2003
				First Named Inventor	John Gary Montana
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	GJE-207CD1

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	R1	JANKOWSKI, K. et al. "Sur Les Oxathianne-1,4-one-2 *" <i>Bulletin de L'Academie Polonaise Des Sciences</i> , 1971, pp. 661-672, Vol. 19, Nos. 11-12, English summary.		
	R2	WITIAK, DONALD T. et al. "cis- and trans-2-Mercaptocyclobutylamines. Synthesis and Antilipolytic Properties in Vitro" <i>Journal of Medicinal Chemistry</i> , 1972, pp. 803-808, Vol. 15, Vol. 8.		
	R3	ROITT, I. M. et al. "Encyclopedia of Immunology", Autoimmune Diseases, 1993, pp. 195-201, Academic Press, Harcourt Brace Jovanovich, publishers.		
	R4			
	R5			
	R6			
	R7			
	R8			
	R9			
	R10			
	R11			
	R12			
	R13			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.